It is important to note that these studies were performed prior to the amendments of the ESC heart failure guidelines and prior to the implementation of ARNIs and SGLT-2 inhibitors in daily clinical practice, potentially explaining the lower mortality of 6.8% in the current cohort [24]. Here, SLC5A2 is linked to heart failure.